1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A

SSZSE:000999
24.78
CNY
-0.22
(-0.88%)
2.50EPS
11.37P/E
37.43BMarket Cap
Mar 22Next Earn
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A
SZSE:000999
(Shenzhen Stock Exchange)

Recent

price

24.78

P/E

ratio

11.37

div

yld

5.46%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.63
3.35
4.18
4.4
4.41
4.79
5.41
6.72
8.1
8.93
8.23
9.4
10.83
14.94
16.56
19.03
19.62
Revenue per Share
0.49
0.46
0.62
0.67
0.63
0.76
0.72
0.79
0.86
1.27
0.96
1.24
1.47
1.72
2.02
2.06
1.98
Basic EPS, GAAP
0.35
0.33
0.43
0.64
0.51
0.56
0.63
0.74
0.79
0.85
0.97
0.61
1.23
2.01
2.17
2.55
- -
Free Cash Flow per Basic Share
0.18
0.18
0.15
0.17
0.18
0.26
0.1
0.11
0.3
0.23
0.26
0.31
0.51
0.64
1.7
0.76
1.35
Dividend per Share
2.71
2.75
3.23
3.62
4.09
4.58
5.21
5.95
6.55
7.71
8.29
9.26
10.18
11.36
11.92
13.32
13.72
Book Value per Share
1.95
1.95
2.16
2.33
2.68
2.46
2.2
2.62
3.17
4.42
4.25
5.2
6.15
5.85
6.4
4.21
4.57
Tangible Book Value per Share
1,661
1,648
1,659
1,658
1,652
1,649
1,659
1,654
1,658
1,658
1,656
1,654
1,669
1,656
1,667
1,661
1,661
Basic Weighted Avg Shares
4,365
5,525
6,943
7,293
7,277
7,900
8,982
11,120
13,428
14,794
13,637
15,544
18,079
24,739
27,617
31,603
32,586
Sales/Revenue/Turnover
21.01
16.66
18.19
18.44
16.71
16.1
14.65
13.76
12.67
12.98
15.8
17.14
16.86
16.08
16.79
15.11
15.66
Operating Margin (%)
118
135
225
213
236
235
284
321
350
337
392
481
524
797
838
1,345
- -
Depreciation Expense
816
760
1,021
1,109
1,036
1,249
1,198
1,302
1,432
2,099
1,597
2,055
2,449
2,853
3,368
3,421
3,284
Net Income, GAAP
16.92
14.03
15.64
16.05
14.88
16.63
16.89
12.63
14.2
16.81
21.46
14.13
15.74
15.47
17.76
14.35
15.82
Effective Tax Rate (%)
18.69
13.76
14.71
15.2
14.24
15.81
13.34
11.71
10.67
14.19
11.71
13.22
13.54
11.53
12.2
10.83
10.08
Profit Margin (%)
1,897
1,511
1,452
2,071
2,452
1,912
1,295
1,349
2,260
3,905
3,630
4,732
3,316
9,575
8,270
12,646
12,650
Working Capital
5
4
26
501
508
500
500
- -
10
10
148
97
156
1,922
270
3,643
2,955
LT Debt
4,732
4,851
5,607
6,197
6,996
7,674
8,721
10,130
11,168
13,078
14,052
15,774
17,533
24,262
25,256
38,472
39,135
Total Equity
19.14
17.23
20.93
18.04
14.35
15.02
11.99
12.99
13.1
16.87
11.66
13.78
14.34
13.87
13.56
11.53
9.7
Return on Invested Capital (%)
17.51
14.65
18.09
17.58
14.33
15.87
13.91
13.08
12.91
17.06
11.56
13.38
14.25
11.51
11.24
7.77
6.03
Return on Capital (%)
19.98
16.85
20.66
19.58
16.26
17.43
14.8
14.1
13.86
17.8
12.07
14.16
15.15
15.86
17.33
16.26
14.92
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,808
2,101
1,554
LT Borrowings
3,514
3,479
2,848
LT Finance Leases
129
115
107
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,664
1,664
1,664
Market Capitalization
47,364
46,498
37,428

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
27,968
27,455
25,065
Cash, Cash Equivalents & STI
8,067
7,636
7,236
Accounts Receivable, Net
8,164
8,209
7,732
Inventories
6,246
6,149
6,115
Total Current Liabilities
15,321
13,518
12,415
Payables & Accruals
- -
- -
- -
ST Debt
2,808
2,101
1,554
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.28%
23.64%
52.33%
Free Cash Flow
21.21%
30.85%
17.43%
Net Income, GAAP
12.12%
16.79%
1.58%
Sales/Revenue/Turnover
15.38%
18.64%
14.43%
Total Cash Common Dividend
33.06%
44.9%
-55.7%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,294
6,812
5,634
7,876
27,617
2025
6,854
7,957
- -
9,616
31,603
2026
8,130
6,884
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.82
0.62
0.34
0.25
2.02
2025
0.77
0.33
- -
0.64
2.06
2026
0.65
0.36
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.9
0.01
0.78
1.7
2025
0.01
0.26
- -
0.47
0.76
2026
0.02
0.6
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) engages in the research, development, production, and sale of pharmaceutical products, health consumer goods, and related healthcare services primarily in China with international distribution. Founded in 1999 and headquartered in Shenzhen, China, the company, a subsidiary of China Resources Pharmaceutical Group Limited, offers core health consumer products (CHC) including cold remedies such as 999 Cold Medication, skin treatments like 999 Dermatitis, gastrointestinal drugs like 399 Weitai Granules, cough medicines, orthopedics products such as bone patches and joint capsules, pediatrics drugs, and dietary nutritional supplements; prescription drugs encompassing anti-tumor, cardiovascular and cerebrovascular therapies including Compound Danshen Drop Pills and Tianmasin Injection, digestive system treatments, anti-infectives like Injectable Cephalosporus, Chinese medicine injections, formula granules, and no-decoction traditional Chinese medicines like Zhengtian Pills and Hemsetong Softgels. It operates over 11 production bases with advanced GMP-certified facilities, supports extensive distribution through multi-channel networks including wholesalers, retail pharmacies exceeding 2,300 outlets, and e-commerce platforms, and invests approximately 5% of revenue in R&D to develop over 300 registered products focused on traditional Chinese medicine, chemical drugs, biopharmaceuticals, and innovative therapies. Recent developments include a June 2025 strategic partnership with HELP Therapeutics via subsidiary Tasly Pharmaceuticals to co-develop and commercialize HiCM-188, an iPSC-derived cell therapy for heart failure; a 2025 acquisition of Tasly strengthening its traditional Chinese medicine and cardiovascular portfolio; exclusive rights acquired with Langyu Group and Bioprojet for innovative drug Huakesi (pitolisant) targeting narcolepsy and sleep disorders, now in China's national reimbursement list; approval in October 2025 of Losolofen Sodium Gel Patch for bone joint inflammation, muscle pain, and post-trauma relief as its first gel patch product; and advancements in AI integration for production, supply chain, and marketing as surveyed by China Resources Group in September 2025.